VTX3232
Neurodegenerative and Cardiometabolic Diseases (e.g., Parkinson's, Alzheimer's, ALS)
Phase 2In Development
Key Facts
Indication
Neurodegenerative and Cardiometabolic Diseases (e.g., Parkinson's, Alzheimer's, ALS)
Phase
Phase 2
Status
In Development
Company
About Ventyx Biosciences
Ventyx Biosciences leverages expertise in medicinal chemistry, structural biology, and immunology to discover and develop differentiated oral therapeutics for diseases with high unmet need. Its clinical-stage pipeline is built around two core platforms: NLRP3 inflammasome inhibitors (with both peripheral and CNS-penetrant candidates) and immunomodulators for inflammatory bowel disease (S1P1R and TYK2). The company's strategic acquisition by Lilly in early 2026 validates its platform and provides significant resources to advance its programs.
View full company profile